Comprehensive Analysis Identified Glycosyltransferase Signature to Predict Glioma Prognosis and TAM Phenotype

Figure 7

Validation of risk models in clinical cohort. (a) Expression levels of 8 risk model glycosyltransferase genes for the high-risk and low-risk groups in our clinical cohort. (b) Correlation of infiltrating macrophages with MGAT4B in the TCGA database. (c) IHC revealed elevated MGAT4B expression in the high-risk group. (d) IF costaining of MGAT4B and macrophages. (e) IF costaining of M2 marker CD206 and macrophages. (f) IF costaining of PD-L1 and macrophages. (g) Validation of the difference in progression-free time between the high- and low-risk groups in our clinical cohort with K-M curve. (h) Validation of the difference in overall survival time between the high- and low-risk groups in our clinical cohort with K-M curve. IHC: immunohistochemistry; IF: immunofluorescence; PD-L1: programmed death-ligand 1; K-M: Kaplan-Meier. and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)